Lorlatinib in advanced ROS1-positive non | 合法藥品大搜索

由 AT Shaw 著作 · 2019 · 被引用 106 次 — Lorlatinib is a potent, brain-penetrant, third-generation tyrosine kinase inhibitor (TKI) that targets ALK and ROS1 with preclinical activity against ... Read More

由 B Solomon 著作 — Lorlatinib is a novel macrocyclic inhibitor of both the ALK and ROS1 kinases. The overall and intracranial activity of lorlatinib in patients with ALK- ... Read More

由 AT Shaw 著作 · 2019 · 被引用 106 次 — Background: Lorlatinib is a potent, brain-penetrant, third-generation tyrosine kinase inhibitor (TKI) that targets ALK and ROS1 with preclinical activity against most ... Read More

由 MJ Hochmair 著作 · 2020 · 被引用 2 次 — In clinical practice, patients with anaplastic lymphoma kinase (ALK)-rearrangement-positive non-small-cell lung cancer commonly receive ... Read More

由 D Killock 著作 · 2020 · 被引用 3 次 — The tyrosine-kinase inhibitors (TKIs) crizotinib and entrectinib have been approved by the FDA for the treatment of ROS1-positive ... Read More

由 JJ Lin 著作 · 2020 · 被引用 6 次 — Background: Lorlatinib is a potent, brain-penetrant ROS1/ALK tyrosine kinase inhibitor (TKI), which has demonstrated efficacy in advanced ROS1 ... Read More

Lorlatinib in ALK- and ROS1-positive NSCLC: the future has a start. Francesco Facchinetti1, Luc Friboulet2. 1Medical Oncology Unit, University Hospital of Parma , ... Read More

2019年11月25日 — “Lorlatinib showed clinical activity in patients with advanced ROS1-positive NSCLC, including those with central nervous system metastases and ... Read More

由 N Frost 著作 · 2020 — The third-generation ALK- and ROS1 inhibitor lorlatinib has demonstrated clinical efficacy in several trials. We here report on the results of the German early ... Read More